Redeye is encouraged by today’s interim data from Vicore’s open-label phase II study in IPF, which a...
Redeye retains its positive view on Transtema following the Q4 report despite a somewhat softer adju...
Pihlajalinna reports Q4 results on Fri, Feb 18. We make small positive revisions to our Q4 estimates...
We expect a solid Q4 report for Ferronordic on 18 February, with sales up 37% y/y and adjusted EBIT ...
Verkkokauppa.com’s Q4 topline fell short of our expectations.
Redeye takes a more positive stance towards Proact following the Q4 report, despite showing declinin...
Redeye comments on G5’s Q4-results which came in close to our expectations.
Redeye believes Sdiptech’s Q4 report and guidance will relieve the soft share price performance seen...
Redeye updates estimates and valuation on Evolution post its Q4-results where we have taken down our...
Redeye leaves a comment on Respiratorious following the announcement of a SEK 45m fully guaranteed r...
Redeye thinks Jondetech's expansion to a software-only offering is good.
Redeye gives a short comment on the announced rights issue and pauses its coverage.
Redeye is encouraged to learn that a health economic analysis carried out by the Swedish Dental and ...
Following Monday's announcement of the Xcimzane licensing deal with Biogen, Redeye is convinced that...
Q4 2021 - ingen kioskvältare Det blev ett svagt avslut på 2021.
Stark omsättningstillväxt men lägre marginal Justerad nettoomsättning i Q4'21 uppgick till 186 mkr (...
Redeye returns with a follow-up note to Genovis’ Q4’21 report.
Redeye provides a preview of its Q4'21 estimates for BONESUPPORT ahead of its report next week.
Plejd växte nettoomsättningen med 31,2 procent. Vi justerar estimat och riktkurs något.
Earlier today, Alzecure reported that the company had received a supportive response from the FDA re...
